Selegiline use is associated with a slower progression in early Parkinson's disease as evaluated by Hoehn and Yahr Stage transition times

Parkinsonism and Related Disorders

Volumn 17, Issue 3, 2011, Pages 194-197

  Zhao, Y J ^a   Wee, H L ^a,b   Au, W L ^c   Seah, S H ^c   Luo, N ^a   Li, S C ^a,d   Tan, L C S ^c  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

^c NATIONAL NEUROSCIENCE INSTITUTE   (Singapore)

^d UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

Hoehn and Yahr stage; Parkinson's disease; Progression; Selegiline

Indexed keywords

AMANTADINE; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; SELEGILINE;

ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR PERFORMANCE; PARKINSON DISEASE; PRIORITY JOURNAL; SCORING SYSTEM; SINGAPORE; TREATMENT DURATION; UNIFIED PARKINSON DISEASE RATING SCALE;

AGED; DISABILITY EVALUATION; DISEASE PROGRESSION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; PROPORTIONAL HAZARDS MODELS; PSYCHIATRIC STATUS RATING SCALES; SELEGILINE;

EID: 79951554114     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2010.11.010     Document Type: Article

References (10)

1. Zhao Y.J., Wee H.L., Chan Y.H., Seah S.H., Au W.L., Lau P.N., et al. Progression of Parkinson's disease as evaluated by Hoehn and Yahr stage transition times. Mov Disord 2010, 25(6):710-716.
2. Olanow C.W., Rascol O., Hauser R., Feigin P.D., Jankovic J., Lang A., et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009, 361(13):1268-1278.
3. Shoulson I., Oakes D., Fahn S., Lang A., Langston J.W., LeWitt P., et al. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of Parkinsonism trial. Ann Neurol 2002, 51(5):604-612.
4. Palhagen S., Heinonen E., Hagglund J., Kaugesaar T., Maki-Ikola O., Palm R. Selegiline slows the progression of the symptoms of Parkinson disease. Neurology 2006, 66(8):1200-1206.
5. Hauser R.A. New considerations in the medical management of early Parkinson's disease: impact of recent clinical trials on treatment strategy. Parkinsonism Relat Disord 2009, 15(Suppl. 3):S17-S21.
6. Goetz C.G., Poewe W., Rascol O., Sampaio C., Stebbins G.T., Counsell C., et al. Movement Disorder society task force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord 2004, 19(9):1020-1028.
7. Grimbergen Y.A., Langston J.W., Roos R.A., Bloem B.R. Postural instability in Parkinson's disease: the adrenergic hypothesis and the locus coeruleus. Expert Rev Neurother 2009, 9(2):279-290.
8. Bohnen N.I., Müller M.L., Koeppe R.A., Studenski S.A., Kilbourn M.A., Frey K.A., et al. History of falls in Parkinson disease is associated with reduced cholinergic activity. Neurology 2009, 73(20):1670-1676.
9. Ebadi M., Brown-Borg H., Ren J., Sharma S., Shavali S., El ReFaey H., et al. Therapeutic efficacy of selegiline in neurodegenerative disorders and neurological diseases. Curr Drug Targets 2006, 7(11):1513-1529.
10. Olanow C.W. Can we achieve neuroprotection with currently available anti- parkinsonian interventions?. Neurology 2009, 72(7 Suppl):S59-S64.